tradingkey.logo

ARS Pharmaceuticals Inc

SPRY
9.840USD
-0.190-1.89%
交易中 美东报价延迟15分钟
972.63M总市值
亏损市盈率 TTM

ARS Pharmaceuticals Inc

9.840
-0.190-1.89%

关于 ARS Pharmaceuticals Inc 公司

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc简介

公司代码SPRY
公司名称ARS Pharmaceuticals Inc
上市日期Dec 04, 2020
CEOLowenthal (Richard E)
员工数量155
证券类型Ordinary Share
年结日Dec 04
公司地址11682 El Camino Real, Suite 300
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92130
电话18587719307
网址https://ars-pharma.com/
公司代码SPRY
上市日期Dec 04, 2020
CEOLowenthal (Richard E)

ARS Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-1143342.00%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-556658.00%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-2969.00%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-1143342.00%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-556658.00%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-2969.00%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 1月31日 周六
更新时间: 1月31日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
其他
61.25%
持股股东
持股股东
占比
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
其他
61.25%
股东类型
持股股东
占比
Hedge Fund
22.26%
Investment Advisor/Hedge Fund
20.07%
Investment Advisor
18.32%
Venture Capital
15.19%
Individual Investor
11.94%
Private Equity
8.39%
Corporation
4.88%
Research Firm
3.80%
Insurance Company
0.59%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
397
88.21M
89.24%
-10.35M
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
10.86M
10.99%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
8.29M
8.39%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
7.50M
7.59%
-106.41K
-1.40%
Sep 30, 2025
Lowenthal (Richard E)
6.83M
6.91%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.88%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.63%
-556.66K
-10.85%
Mar 31, 2025
Rubric Capital Management LP
4.50M
4.55%
+3.21M
+247.52%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
4.4%
+419.68K
+10.68%
Sep 30, 2025
SR One Capital Management, LP
4.01M
4.06%
--
--
Sep 30, 2025
abrdn Inc.
3.10M
3.13%
+1.59M
+106.11%
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
0.38%
State Street SPDR S&P Biotech ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Principal U.S. Small-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares US Small-Cap Equity Factor ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.04%
查看更多
ALPS Medical Breakthroughs ETF
占比0.38%
State Street SPDR S&P Biotech ETF
占比0.32%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
占比0.16%
ProShares Ultra Nasdaq Biotechnology
占比0.11%
Principal U.S. Small-Cap ETF
占比0.09%
Invesco Nasdaq Biotechnology ETF
占比0.08%
iShares US Small-Cap Equity Factor ETF
占比0.05%
iShares Biotechnology ETF
占比0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
占比0.04%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI